TW201302800A - Ｓｅｍａ５ｂ胜肽及含其之疫苗 - Google Patents

Ｓｅｍａ５ｂ胜肽及含其之疫苗 Download PDF

Info

Publication number
TW201302800A
TW201302800A TW101120218A TW101120218A TW201302800A TW 201302800 A TW201302800 A TW 201302800A TW 101120218 A TW101120218 A TW 101120218A TW 101120218 A TW101120218 A TW 101120218A TW 201302800 A TW201302800 A TW 201302800A
Authority
TW
Taiwan
Prior art keywords
peptide
antigen
cytotoxic
sema5b
cell
Prior art date
Application number
TW101120218A
Other languages
English (en)
Chinese (zh)
Inventor
角田卓也
大澤龍司
吉村祥子
渡邊朝久
中山岳
中村祐輔
Original Assignee
腫瘤療法 科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 腫瘤療法 科學股份有限公司 filed Critical 腫瘤療法 科學股份有限公司
Publication of TW201302800A publication Critical patent/TW201302800A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
TW101120218A 2011-06-10 2012-06-06 Ｓｅｍａ５ｂ胜肽及含其之疫苗 TW201302800A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161495819P 2011-06-10 2011-06-10

Publications (1)

Publication Number Publication Date
TW201302800A true TW201302800A (zh) 2013-01-16

Family

ID=47295783

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101120218A TW201302800A (zh) 2011-06-10 2012-06-06 Ｓｅｍａ５ｂ胜肽及含其之疫苗

Country Status (14)

Country Link
US (1) US9187556B2 (enExample)
EP (1) EP2718435A4 (enExample)
JP (1) JP2014519311A (enExample)
KR (1) KR20140026543A (enExample)
CN (1) CN103620033A (enExample)
AU (1) AU2012265677A1 (enExample)
BR (1) BR112013031056A2 (enExample)
CA (1) CA2838633A1 (enExample)
IL (1) IL228995A0 (enExample)
MX (1) MX2013014489A (enExample)
RU (1) RU2013158399A (enExample)
SG (1) SG195047A1 (enExample)
TW (1) TW201302800A (enExample)
WO (1) WO2012169200A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CN110191703B (zh) 2017-01-25 2022-04-08 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
WO2025072522A1 (en) * 2023-09-29 2025-04-03 The Regents Of The University Of California Neojunction-derived cancer antigen epitopes, specific t cell receptors (tcrs) for immunotherapy, and discovery platform for the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CN101278059A (zh) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 诊断和治疗肾细胞癌的方法
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
EP2837636B1 (en) * 2007-01-29 2018-04-11 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof

Also Published As

Publication number Publication date
US20140178409A1 (en) 2014-06-26
US9187556B2 (en) 2015-11-17
SG195047A1 (en) 2013-12-30
EP2718435A1 (en) 2014-04-16
CA2838633A1 (en) 2012-12-13
BR112013031056A2 (pt) 2016-11-29
KR20140026543A (ko) 2014-03-05
WO2012169200A1 (en) 2012-12-13
EP2718435A4 (en) 2014-11-26
RU2013158399A (ru) 2015-07-20
AU2012265677A1 (en) 2014-01-16
CN103620033A (zh) 2014-03-05
JP2014519311A (ja) 2014-08-14
MX2013014489A (es) 2014-03-27
IL228995A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
TWI658049B (zh) Ｋｎｔｃ２胜肽及含此胜肽之疫苗
TWI568444B (zh) Ｎｅｉｌ３胜肽及其疫苗
US20160310586A1 (en) TOPK Peptides and Vaccines Including the Same
US9187556B2 (en) SEMA5B peptides and vaccines including the same
TWI485245B (zh) 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
TWI564303B (zh) Ｍｐｈｏｓｐｈ１胜肽及含其之疫苗
TWI632162B (zh) Ｕｂｅ２ｔ胜肽與含此之疫苗
US9585948B2 (en) TOMM34 peptides and vaccines including the same
RU2570560C2 (ru) Пептиды hjurp и содержащие их вакцины
US8697631B2 (en) TMEM22 peptides and vaccines including the same
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
EP2507257A1 (en) Mybl2 peptides and vaccines containing the same
WO2014087626A1 (en) Sema5b peptides and vaccines containing the same
TW201300423A (zh) Ｃ１８ｏｒｆ５４胜肽與含此胜肽之疫苗
TW201512223A (zh) Ｓｍｙｄ３胜肽及含此之疫苗
TW201439114A (zh) Ｃｄｃａ５胜肽及含此胜肽之疫苗
TW201443078A (zh) Ｃ１２ｏｒｆ４８胜肽及含此胜肽之疫苗